These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29067343)

  • 1. Alzheimer's disease drug development pipeline: 2017.
    Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug development pipeline: 2018.
    Cummings J; Lee G; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2018; 4():195-214. PubMed ID: 29955663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's drug-development pipeline: 2016.
    Cummings J; Morstorf T; Lee G
    Alzheimers Dement (N Y); 2016 Nov; 2(4):222-232. PubMed ID: 29067309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
    Tamaoka A
    Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease drug development pipeline: 2023.
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2023; 9(2):e12385. PubMed ID: 37251912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposed agents in the Alzheimer's disease drug development pipeline.
    Bauzon J; Lee G; Cummings J
    Alzheimers Res Ther; 2020 Aug; 12(1):98. PubMed ID: 32807237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease drug development pipeline: 2019.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2019; 5():272-293. PubMed ID: 31334330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease drug development pipeline: 2020.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2020; 6(1):e12050. PubMed ID: 32695874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2024; 10(2):e12465. PubMed ID: 38659717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who funds Alzheimer's disease drug development?
    Cummings J; Bauzon J; Lee G
    Alzheimers Dement (N Y); 2021; 7(1):e12185. PubMed ID: 34095442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease drug development pipeline: 2021.
    Cummings J; Lee G; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2021; 7(1):e12179. PubMed ID: 34095440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease drug-development pipeline: few candidates, frequent failures.
    Cummings JL; Morstorf T; Zhong K
    Alzheimers Res Ther; 2014; 6(4):37. PubMed ID: 25024750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the horizon-the value and promise of the global pipeline of Alzheimer's disease therapeutics.
    Cole MA; Seabrook GR
    Alzheimers Dement (N Y); 2020; 6(1):e12009. PubMed ID: 32405530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy for Alzheimer's disease: what's new on the horizon?
    Khoury R; Gallop A; Roberts K; Grysman N; Lu J; Grossberg GT
    Expert Opin Pharmacother; 2022 Aug; 23(11):1305-1323. PubMed ID: 35793398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022.
    Abdelnour C; Gonzalez MC; Gibson LL; Poston KL; Ballard CG; Cummings JL; Aarsland D
    Neurol Ther; 2023 Jun; 12(3):727-749. PubMed ID: 37017910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.